N
BIIB icon

Natixis’s Biogen BIIB Stock Holding History

Natixis’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40,000
Closed -$11.1M – 996
2022
Q4 		$11.1M Buy
40,000
+20,000
+100% +$5.65M 0.06% 255
2022
Q3 		$5.34M Sell
20,000
-5,065
-20% -$1.08M 0.03% 392
2022
Q2 		$5.15M Buy
+25,065
New +$5.12M 0.02% 439

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Natixis's BIIB Position: Q1 2026 in Review

Natixis reduced its Biogen (BIIB) stake by 22% in Q1 2026, selling an estimated $1.2M and leaving 22,585 shares worth $4.14M. The position accounts for 0.01% of the portfolio, ranked #466.

Natixis first reported a position in BIIB in Q2 2013 and has held it in 49 quarters since. The position peaked at $63.3M in Q1 2019. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Natixis held 22,585 shares of Biogen worth $4.14M as of Q1 2026.
  • Natixis sold 6,519 Biogen shares in Q1 2026, an estimated $1.2M.
  • Biogen made up 0.01% of Natixis's portfolio in Q1 2026, its #466 holding.
  • Natixis first reported a position in Biogen in Q2 2013 and has held it in 49 quarters since.
  • Natixis's Biogen position peaked at $63.3M in Q1 2019.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.